Issue 1, 2025

On-demand release of encapsulated ZnO nanoparticles and chemotherapeutics for drug delivery applications

Abstract

Nanomedicines offer high promise for the treatment of various diseases, and numerous novel approaches using nanomaterials have been developed over the years. In this report, we introduce a new strategy utilizing ZnO nanoparticles (nZnO) to trigger the rapid release of lipid-encapsulated therapeutics upon photo-irradiation with UV light (365 nm). In vitro studies demonstrate that encapsulation of nZnO effectively eliminates the cytotoxicity of nZnO, but this can be re-established upon release from the lipid coating. Using 5(6)-carboxyfluorescein as a model for hydrophilic drug loading, we show the ability to co-load drugs with nZnO into liposomes. Kinetic studies reveal the ability to release the majority of the dye within 60 minutes post-photo-irradiation and provide insights into factors that impact release kinetics. To further explore this, Jurkat T cell leukemia and T47D breast cancer cells were treated with co-encapsulated nZnO and the hydrophobic cancer drug paclitaxel. These studies revealed enhanced toxicity of the triggered release groups with an extreme difference noted in the viability profiles of the T47D breast cancer cell model. Taken together, these studies indicate that this system of co-encapsulating nZnO and chemotherapeutic drugs has the potential to minimize systemic toxicity, by controlling therapeutic release, while allowing for the localized selective destruction of cancer.

Graphical abstract: On-demand release of encapsulated ZnO nanoparticles and chemotherapeutics for drug delivery applications

Supplementary files

Article information

Article type
Paper
Submitted
28 Jun 2024
Accepted
17 Oct 2024
First published
06 Nov 2024
This article is Open Access
Creative Commons BY-NC license

RSC Pharm., 2025,2, 82-93

On-demand release of encapsulated ZnO nanoparticles and chemotherapeutics for drug delivery applications

J. E. Eixenberger, C. B. Anders, R. Hermann, K. Wada, K. M. Reddy, R. J. Montenegro-Brown, D. Fologea and D. G. Wingett, RSC Pharm., 2025, 2, 82 DOI: 10.1039/D4PM00189C

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements